Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Candel Therapeutics (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing biological immunotherapies for cancer treatment, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's President and CEO, Paul Peter Tak, M.D., Ph.D., FMedSci, will deliver a presentation on August 13, 2025, at 2:00 PM EST in Boston, MA.

The presentation will be accessible via webcast through Candel's investor relations website, with a replay available for up to 90 days after the event.

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA.

Date: Wednesday, August 13, 2025
Time: 2:00-2:25PM EST
Webcast Link: Canaccord Genuity / Candel Presentation

A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform.

The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.

CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms; and expectations regarding the potential benefits conferred by Regenerative Medicine Advanced Therapy Designation, Fast Track Designation, Orphan Drug Designation or Orphan Designation. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
Vice President
ICR Healthcare
CandelPR@icrhealthcare.com

FAQ

When is Candel Therapeutics (CADL) presenting at the Canaccord Genuity Conference?

Candel Therapeutics will present on Wednesday, August 13, 2025, from 2:00-2:25 PM EST at the Canaccord Genuity Growth Conference in Boston.

Who will be presenting for Candel Therapeutics (CADL) at the Canaccord conference?

Paul Peter Tak, M.D., Ph.D., FMedSci, who serves as Candel's President and Chief Executive Officer, will present at the conference.

How can investors access Candel Therapeutics' (CADL) Canaccord conference presentation?

Investors can access the presentation through a live webcast available in the Events and Presentations section under News & Events tab on candeltx.com. A replay will be available for 90 days after the presentation.

What is Candel Therapeutics' (CADL) main business focus?

Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer.